Stockscreener 앱 받기
2.36
7.76%
0.17
시간 외 거래:
2.37
0.01
+0.42%
Immunitybio Inc 주식(IBRX)의 최신 뉴스
ImmunityBio, Moderna among winners of EU drug recommendations this week - MSN
ImmunityBio’s HCW9218 Study Completion: A Potential Game-Changer for Pancreatic Cancer Treatment - TipRanks
Should EMA’s Conditional Nod for ANKTIVA in High-Risk Bladder Cancer Require Action From ImmunityBio (IBRX) Investors? - Yahoo Finance
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's Why - MarketBeat
ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion - Insider Monkey
D. Boral Capital Maintains ImmunityBio (IBRX) Buy Recommendation - Nasdaq
Jefferies Maintains ImmunityBio (IBRX) Buy Recommendation - Nasdaq
ImmunityBio Gains Momentum: Bladder Cancer Care Focus - StocksToTrade
Jefferies raises Immunitybio stock price target to $9 on European regulatory progress - Investing.com
ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy - Benzinga
CHMP recommends Immunitybio's Anktiva, Cytokinetics' Myqorzo - BioWorld MedTech
Immunitybio stock rises after positive EMA recommendation for bladder cancer therapy - Investing.com Australia
Is ImmunityBio Inc a good long term investmentSector Rotation Strategies & Achieve Consistent Profits - earlytimes.in
ImmunityBio Says European Medicines Agency Recommends Conditional Marketing Authorization for Anktiva with BCG for Non-Muscle Invasive Bladder Cancer - marketscreener.com
ImmunityBio Receives EMA Recommendation for ANKTIVA in Europe - TradingView — Track All Markets
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe - Business Wire
Armistice Capital LLC Acquires New Position in ImmunityBio, Inc. $IBRX - MarketBeat
10 Big Names Leaving Wall Street in the Dust; 4 at Fresh Highs - Insider Monkey
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
Does Anktiva-Driven Revenue Momentum Reshape the Bull Case For ImmunityBio (IBRX)? - Sahm
ImmunityBio, Inc. (IBRX): A Bull Case Theory - Finviz
ImmunityBio, Inc. (IBRX): A bull case theory - MSN
Can ImmunityBio Stock Hold Up When Markets Turn? - Trefis
Is ImmunityBio Inc. stock a smart buy before Fed meeting2025 Price Targets & Safe Entry Zone Tips - Newser
Will ImmunityBio Inc. (26CA) stock benefit from mergersJuly 2025 Price Swings & Breakout Confirmation Alerts - Newser
How ImmunityBio Inc. (26CA) stock responds to bond marketJuly 2025 Drop Watch & Intraday High Probability Alerts - Newser
Piper Sandler Remains a Buy on ImmunityBio (IBRX) - The Globe and Mail
ImmunityBio Earnings Notes - Trefis
Is ImmunityBio Inc. (26CA) stock undervalued at current priceWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
ImmunityBio (NASDAQ:IBRX) Trading Down 5.4%Should You Sell? - MarketBeat
Lawmakers Invited to FDA Meeting for Soon-Shiong’s Drug - Bloomberg.com
ImmunityBio (IBRX) Slashes 9% on Lack of Leads - Finviz
Lawmakers Invited to FDA Meeting for Patrick Soon-Shiong’s Drug - Bloomberg.com
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs (NASDAQ:IBRX) - Seeking Alpha
Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? - MSN
ImmunityBio (IBRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
ImmunityBio (NASDAQ:IBRX) Sees Large Volume IncreaseStill a Buy? - MarketBeat
ImmunityBio Stock Rises Despite Financial Challenges - timothysykes.com
Can ImmunityBio Inc. (26CA) stock sustain free cash flowRisk Management & Reliable Volume Spike Trade Alerts - Newser
Geode Capital Management LLC Acquires 1,487,849 Shares of ImmunityBio, Inc. $IBRX - MarketBeat
Assessing ImmunityBio After Recent Cancer Immunotherapy Headlines and Ongoing Stock Volatility - Yahoo Finance
A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally - Yahoo Finance
ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences - Insider Monkey
ImmunityBio Skyrockets on Positive Trial Results and Sales Growth - StocksToTrade
ImmunityBio Boosts Outlook with Strong Revenue Growth and Clinical Advances - timothysykes.com
ImmunityBio’s Immunotherapy Focus Boosts Market Expectations - StocksToTrade
ImmunityBio Gains Momentum with Strong ANKTIVA Sales and Clinical Advances - timothysykes.com
1.08%
0.91%
자본화:
|
볼륨(24시간):